Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary
Tommaso Giarratano(Istituto Oncologico Veneto), Valentina Guarneri(Istituto Oncologico Veneto), Silvia Michieletto(Istituto Oncologico Veneto), Ilaria Polico(Istituti di Ricovero e Cura a Carattere Scientifico), Maria Vittoria Dieci(Istituto Oncologico Veneto), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Federica Miglietta(University of Padua), Laura Evangelista(Istituto Oncologico Veneto), Vassilena Tsvetkova(University of Padua)
Cited by 10
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226